15.31
Schlusskurs vom Vortag:
$15.20
Offen:
$15
24-Stunden-Volumen:
1.66M
Relative Volume:
0.75
Marktkapitalisierung:
$1.32B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-5.1723
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
-6.93%
1M Leistung:
-1.54%
6M Leistung:
+36.21%
1J Leistung:
-22.75%
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SNDX
Syndax Pharmaceuticals Inc
|
15.31 | 1.38B | 139.71M | -209.36M | -160.60M | -2.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-10 | Fortgesetzt | Stifel | Buy |
2025-09-04 | Fortgesetzt | Guggenheim | Buy |
2025-08-05 | Bestätigt | BTIG Research | Buy |
2025-07-10 | Eingeleitet | Goldman | Buy |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-06-28 | Eingeleitet | Jefferies | Buy |
2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
2023-12-22 | Eingeleitet | Mizuho | Buy |
2023-10-25 | Eingeleitet | BofA Securities | Buy |
2023-10-11 | Eingeleitet | Goldman | Buy |
2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
2023-07-11 | Eingeleitet | Guggenheim | Buy |
2023-04-17 | Fortgesetzt | BTIG Research | Buy |
2023-01-31 | Eingeleitet | Stifel | Buy |
2023-01-03 | Eingeleitet | JP Morgan | Overweight |
2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
2022-02-15 | Eingeleitet | Goldman | Buy |
2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
2021-05-25 | Eingeleitet | Citigroup | Buy |
2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
2020-12-03 | Eingeleitet | Stifel | Buy |
2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
2017-03-02 | Eingeleitet | Instinet | Buy |
2016-10-07 | Eingeleitet | Guggenheim | Buy |
2016-03-28 | Eingeleitet | Citigroup | Buy |
2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Path To Profitability - 富途牛牛
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Why Syndax Pharmaceuticals Inc. stock is rated strong buyQuarterly Risk Review & Long-Term Capital Growth Strategies - newser.com
Technical analysis overview for Syndax Pharmaceuticals Inc. stock2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.9%Here's What Happened - MarketBeat
Syndax Pharmaceuticals Inc. stock momentum explainedJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
Real time pattern detection on Syndax Pharmaceuticals Inc. stockJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - newser.com
Heatmap analysis for Syndax Pharmaceuticals Inc. and competitors2025 EndofYear Setup & AI Driven Stock Movement Reports - newser.com
Syndax Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
Evaluating Syndax Pharmaceuticals Inc. with trendline analysis2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Order flow analysis tools used on Syndax Pharmaceuticals Inc.July 2025 Action & Pattern Based Trade Signal System - newser.com
Will Syndax Pharmaceuticals Inc. stock see insider buying2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-10 04:00:50 - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Analyzing drawdowns of Syndax Pharmaceuticals Inc. with statistical toolsPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Published on: 2025-10-09 05:04:06 - newser.com
Should you hold or exit Syndax Pharmaceuticals Inc. nowJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentValue Traps to Avoid & Small Investment Portfolio - earlytimes.in
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Research Analysts Offer Predictions for SNDX FY2027 Earnings - MarketBeat
Will October's FDA Decision Be A Shot In The Arm For Revuforj's Expansion? - RTTNews
Measuring Syndax Pharmaceuticals Inc.’s beta against major indices2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Comparing Syndax Pharmaceuticals Inc. in custom built stock radarsProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision - Yahoo Finance
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - The Sunday Guardian
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - MarketScreener
Does Syndax Pharmaceuticals Inc. qualify in momentum factor screeningStop Loss & Daily Entry Point Trade Alerts - newser.com
138,900-Share Grant: Syndax Awards to 10 New Employees; Options Vest Monthly Under Inducement Plan - Stock Titan
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
What analysts say about Syndax Pharmaceuticals Inc stockEarnings Revision Updates & Minimize Portfolio Damage with Warnings - earlytimes.in
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from BTIG Research - MarketBeat
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):